Alkeus Pharmaceuticals doses first patient in Phase 3 Stargardt trial
Alkeus Pharmaceuticals has dosed the first patient in the NORTHSTAR study, its pivotal global Phase 3 trial of oral gildeuretinol (ALK-001) for Stargardt disease — a rare, progressive inherited retinal condition that causes irreversible central vision loss and for which no FDA-approved treatment exists. The first dose was administered at Erie Retina Research in Pennsylvania.
Stargardt disease affects an estimated 50,000 to 60,000 people in the United States alone. It is caused by a defect in the ABCA4 protein, which leads to the accumulation of toxic vitamin A dimers that irreversibly damage the retinal epithelium, producing progressive loss of central vision typically beginning in childhood or early adulthood.
Trial design
NORTHSTAR is a randomised, placebo-controlled, double-masked 24-month study that will enrol approximately 230 participants aged 8 to 45 with advanced Stargardt disease and atrophic lesions at baseline. The primary endpoint is the rate of atrophic lesion growth from months 6 to 24, measured by fundus autofluorescence (FAF). The key secondary endpoint is preservation of visual acuity, assessed by low luminance visual acuity (LLVA) — a functional measure considered by investigators to be more sensitive than standard best-corrected visual acuity in detecting early functional decline.
The study design was agreed jointly by the FDA and the European Medicines Agency. Alkeus plans to run approximately 55 sites across more than 11 countries. The company said it is building on clinical experience gathered in prior studies that together treated around 400 patients, with a maximum treatment duration of more than seven years.
Gildeuretinol works by reducing vitamin A dimerisation without disrupting the visual cycle — the biochemical pathway by which the retina regenerates photopigment. The company said prior trials reported no incidences of chromatopsia, dark adaptation delays, or night blindness, adverse effects associated with other retinoid-targeting approaches that do modulate the visual cycle.
David Almeida, principal investigator at Erie Retina Research, said: "There remains a significant unmet need in Stargardt disease, and continued progress in research is important for patients and families affected by this condition."
Regulatory status and competitive context
Gildeuretinol carries Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations from the FDA. The EMA has granted orphan medicinal product status for non-syndromic inherited retinal dystrophies due to ABCA4 defects, which encompasses Stargardt disease. The breadth of these designations reflects both the severity of the condition and the absence of approved alternatives, and will be meaningful to any eventual regulatory review timeline.
The inherited retinal disease space has seen growing investment in gene therapy approaches — CRISPR-based and adeno-associated virus (AAV) platforms have been explored by a number of academic and commercial groups for ABCA4-linked disease. Gildeuretinol's oral, small-molecule mechanism distinguishes it from these approaches and may offer practical advantages in a paediatric population where ocular gene delivery presents procedural and immunological challenges. Alkeus is a private company backed by Bain Capital Life Sciences and has not disclosed a funding runway or commercial partnership in this announcement.
Stargardt disease's relatively small patient pool — combined with the Rare Pediatric Disease designation, which can generate a transferable FDA priority review voucher on approval — means a successful NORTHSTAR readout could carry both clinical and commercial significance. The 24-month treatment period puts a primary data readout on or around mid-2028, assuming enrolment proceeds broadly on schedule.